Matthew Perry Investigation: Can Ketamine Kill Someone?

Updated Aug 17, 2024 | 12:00 PM IST

SummaryNew evidence has come up in the investigation of Matthew Perry, 'Friends' Chandler Bing's death on October 28. This evidence points to an overdose of ketamine. What is ketamine and how does it affect you? Read now.
Matthew Perry Investigation Can Ketamine Kill Someone

Credits: IMDb

“I'm not great at the advice. Can I interest you in a sarcastic comment?”

Friends Actor Matthew Perry

This is what ‘Friends’ actor Matthew Perry’s character Chandler Bing was known for. He was known for being funny. However, he had his own struggles in his personal life and those struggles were acute depression. He was treating it with ketamine infusion therapy which is legal in the US and the UK.

What is Ketamine infusion therapy?

Ketamine is an anaesthetic used to treat depression, anxiety and pain under supervised and controlled medical settings. However, it does have its side effects, which can lead to distortion of sight, sound and time. It can also produce calming and relaxing effects.

Ketamine increases a person’s heart rate and blood pressure. If overdosed, it can leave users confused and agitated and can cause them to hurt themselves without even realising it. It can also lead to liver damage and bladder problems.

However, when used in moderation and under the supervision of medical doctors, it can treat depression where traditional antidepressants have failed.

Prof Rupert McShane, a University of Oxford psychiatrist who runs an NHS ketamine treatment clinic told BBC that ketamine “probably turns off the area of the brain that is involved in disappointment.”

Can Ketamine Infusion Therapy Kill Someone?

In simple terms, it cannot, be if the dosage is given in a controlled setting and as prescribed. Ketamine infusion therapy uses drugs in small doses than those used for anaesthesia. It acts faster than traditional anti-depressants, but the effects also wear off way quickly. Which is why it is important to monitor patients’ mental state for relapsing back into depression and discouraging them from overdosing on it.

There are ways of giving people ketamine. One of the ways is through “infusing”, which means to use an IV drip. However, injections, nasal sprays and capsules are also methods used to give people ketamine.

Since the dosage of ketamine used in the infusion treatment is small, it being the reason of actor Perry’s death was ruled out. The medical examiner also noted that Perry’s last ketamine infusion therapy session happened more than a week before his death, which means by the time he had died, it must have worn off.

So, What Happened To Perry?

Though Perry’s last session was more than a week before, his post-mortem showed that his blood contained a high concentration of ketamine. He had died of the “acute effects” of ketamine.

If it was not his session, then how did he get ketamine?

Prosecutors alleged that his assistant gave him at least 27 shots of ketamine in four days before his death, reported BBC.

Perry has been open about his personal struggles and this is what the doctors and dealers used against him. Martin Estrada, the US attorney for California’s Central District told the BBC that people took advantage of his condition. They charged him 165 times more than what vials of ketamine cost.

Names that have come up include Dr Salvador Plasencia, drug dealers “Ketamine Queen” aka Jasveen Sangha and Eric Fleming, and Perry’s live-in assistant Kenneth Iwamasa.

Who Are These Names And What Did They Do?

Ketamine Queen or Sangha supplied drugs that led to Perry’s death. Her home was a “drug-selling emporium,” said Estrada. More than 80 vials of ketamine, and thousands of pills including methamphetamine, cocaine and Xanax were allegedly found in her house known as the “Sangha Stash House.”

Sangha is known to deal with high-end celebs and was a “major source of supply for ketamine to others as well as Perry,” said Estrada.

Dr Plasencia called Perry a “moron” while charging him $2,000 for vials that cost only $12. He sold Perry 20 vials of ketamine between September and October 2023, costing $55,000.

He was the one who taught Iwamasa, who had no medical knowledge to inject the drug. This is after he knew that “Perry’s ketamine addiction was spiralling out of control,” as per what the investigators told the BBC.

Another dealer Fleming was told by Sangha to “delete all our messages.” While Fleming pleaded guilty to conspiring to distribute drugs unlawfully, he also allegedly messaged Sangha: “Please call...Got more info and want to bounce ideas off you. I’m 90% sure everyone is protected. I never dealt with [Perry] only his assistant. So the assistant was the enabler.”

The court documents also revealed that he asked Sangha on whether the ketamine stays in your system or “is it immediately flushed out.”

Dr Pepper, Bots, Cans

The people who allegedly exploited Perry used coded language for ketamine and called it “Dr Pepper”, “bots”, or “cans.”

Selling overpriced drugs, taking advantage of Perry’s mental condition and falsifying medical records to make the drugs given to him look legitimate by Dr Plasencia is what took Perry’s life.

Iwamasa is said to have administered more than 20 shots of ketamine and three on the day Perry died. Whereas ketamine is only administered by a physician. Authorities also found that weeks before Perry’s death, Dr Plasencia allegedly bought 10 vials of ketamine and intended to sell to Perry.

He also injected Perry with a large dose, two days later. This caused him to “freeze up” and spiked his blood pressure.

When I Die, I Want Helping Others To Be The First Thing That’s Mentioned

Perry had always been open about his drug addictions, struggles with alcohol and his depression. He said that his openness would help others who are also struggling and wanted to be remembered by his quote which also is on the homepage of the Mattew Perry Foundation that helps others struggling with the disease of addiction: “When I die, I want helping others to be the first thing that’s mentioned.”

Five arrests have been made in the case so far.

End of Article

AIIMS And ISRO Sign MoU To Advance Research In Space Medicine

Updated Mar 10, 2026 | 12:40 PM IST

SummaryAIIMS and ISRO signed an MoU to advance space medicine research, focusing on human physiology and health in microgravity. The collaboration aims to strengthen India’s human spaceflight capabilities and biomedical research as the country progresses toward its 2047 vision.
AIIMS And ISRO Sign MoU To Advance Research In Space Medicine

Credits: Dr P Sarat Chandra (LinkedIn)

All India Institute of Medical Sciences (AIIMS) and the Indian Space Research Organisation (ISRO) signed a Memorandum of Understanding (MoU) on Monday to collaborate on advancing research in space medicine.

The MoU was signed between M Srinivas, Director (AIIMS), New Delhi and Dinesh Kumar Singh, Director, Human Space Flight Centre (HSFC), ISRO. The event brought together senior leadership from AIIMS and ISRO, including ISRO Chairman V Narayanan and Secretary, Department of Space, as well as Deans, Heads of Departments, faculty members, and studies from AIIMS New Delhi.

Also Read: Is There A Link Between Your Kidney Health And Other Chronic Diseases? Study Says Yes

As per the news agency Asian News International (ANI), a press release of the collaboration noted for a cooperative framework for ground-based and space-based research in Space Medicine. The press release also noted that the research will cover areas like human physiology, cardiovascular and autonomic regulation, musculoskeletal health in microgravity, microbiome and immunology, genomics and biomarkers and behavioral health.

“This MoU will give us the escape velocity to venture together into the field of space medicine. Collaborative research between AIIMS and ISRO will benefit patients, the nation, and ultimately humankind. As India moves toward Viksit Bharat by 2047, we hope to emerge as a Vishwaguru in space medicine as well,” said Prof M Srinivas, Director, AIIMS, New Delhi.

AIIMS signs MoU with ISRO

Chairman of ISRO Dr V Narayanan and Secretary, Department of Space also highlighted India’s remarkable journey in space programme. He noted how India evolved from the time when rockets and equipment were transported on bicycles and bullock carts to today, where it is going to be leading medical and research institutions like AIIMS to strengthen India’s human spaceflight capabilities.

The programme also featured a presentation on AIIMS New Delhi’s ongoing work in space medicine research, delivered by Prof. KK Deepak, former Head of the Department of Physiology. The event was attended by Heads of Departments and faculty members from across AIIMS New Delhi, along with representatives from the Resident Doctors Association (RDA), the AIIMS Student Association (ASA), and the Society of Young Scientists (SYS).

The collaboration represents an important step toward enhancing India’s capabilities in human spaceflight and biomedical research. It also aligns with the country’s broader scientific ambitions as India moves toward its centenary in 2047 and the vision of Viksit Bharat.

Read: Sunita Williams Retires After 27 Years: Health Challenges She Faced After Spending 600+ Days in Space

What Do We Already Know About Space Medicine?

As per a 2017 study in the British Journal of Anaesthesia, space medicine is fundamental to the human exploration of space. It supports survival, function and performance in this challenging as potentially lethal environment. It is international, intercultural and interdisciplinary, operating at the boundaries of exploration, science, technology and medicine.

Space medicine specialists play a crucial role in safeguarding astronauts and other spaceflight participants. Known as “flight surgeons,” they help develop strategies to protect the health, safety, and performance of space travellers in the extreme conditions of space. Their responsibilities span every stage of a mission — from selection and training to in-flight care, post-mission rehabilitation, and monitoring long-term health effects.

With inputs from ANI

End of Article

Virus Without Vaccine Hits California; No Need To Worry, Say Public Health Officials

Updated Mar 10, 2026 | 10:38 AM IST

SummaryHuman metapneumovirus (HMPV), a respiratory virus without a vaccine, is being detected in California wastewater and rising seasonally across the US. Doctors say it usually causes mild symptoms but can trigger pneumonia or bronchitis in vulnerable groups.
Virus Without Vaccine Hits California; No Need To Worry, Say Public Health Officials

Credits: Canva

Sick days are again piling up with a respiratory disease, not COVID-19 or the flu. This disease is most likely the one Americans have not heard of. This is HMPV or human metapneumovirus. Doctors have asked people to stay vigilant as seasonal flu virus could lead to pneumonia and bronchitis, and it is spreading in California wastewater and around the country. However, as per public health officials, there is nothing to get worried at this point.

Also Read: Is There A Link Between Your Kidney Health And Other Chronic Diseases? Study Says Yes

As per the public database WasterwaterScan Dashboard, high levels of HMPV were detected across Northern California cities. The highest levels were reported in Redwood City, whereas elevated levels were found in San Francisco Bay Area and Napa's Wine Country. What's more dangerous is that this virus is without a vaccine.

The good news is that in other parts of country HMPV remains lower. However, the Centers for Disease Control and Prevention (CDC) noted that data from October 2025 shows the cases are trending up, especially during winter and spring.

Dr. Matthew Binnicker, director of the Clinical Virology Laboratory at Mayo Clinic, as reported by The Independent said, "In the late winter, early spring, it can account for five percent to 10 percent of all the respiratory infections that we diagnose in the United States. So it's definitely out there." Experts explain that other viruses like HMPV or influenza get a chance when COVID is quieter.

Read: HMPV Virus Cases Surging In California, New Jersey: Is It Dangerous?

Virus Without A Vaccine: What Is HMPV?

HMPV was first discovered in 2001 and is part of the Pneumoviridae family along with the Respiratory syncytial virus (RSV).

HMPV most likely spreads from an infected person to others through:

  • the air by coughing and sneezing
  • close personal contact, such as touching or shaking hands
  • touching objects or surfaces that have the viruses on them, then touching the mouth, nose, or eyes

In the US, HMPV circulates in predictable patterns each year, typically beginning in winter and lasting through spring.

The usually self-limiting and mild symptoms typically last 4 to 5 days. These include:

  • cough
  • fever
  • nasal congestion
  • shortness of breath

People at risk include:

  • elderly people
  • children
  • people with comorbidities

"The HMPV is not deadly, and there is no evidence of mortality or a severe transmission rate," former Indian Council of Medical Research (ICMR) scientist, Dr. Raman Gangakhedkar, told IANS, during the virus's outbreak in India in 2025.

“The virus may cause pneumonitis-like illness, but the mortality rates are almost unknown so far. HMPV has a global prevalence of about 4 per cent,” he added.

While no vaccine or treatment can prevent HMPV infection, to avoid the infection, individuals must:

Practice good hygiene and cover your mouth and nose with a tissue when coughing or sneezing, or use your elbow, not your hands, for it. And wash your hands properly, especially in healthcare settings.

Why Are People Hearing About The Virus Without Vaccine Now?

The reason people have not heard about it before is because its symptoms are nearly indistinguishable from other respiratory infections, so often it could go undiagnosed. Furthermore, earlier the COVID cases and influenza cases sparked up, which deviated the attention from HMPV. Now, with the season gone, and increased awareness around respiratory illnesses, greater attention to viruses like HMPV is also paid.

End of Article

1 In 7 Indians Affected By Mental Health Disorders; Govt To Launch NIMHANS-2 To Boost Care

Updated Mar 9, 2026 | 10:00 PM IST

SummaryExperts at the government-led Post-Budget Webinar series highlighted that several states continue to face a treatment gap ranging from 70 to 90 percent. Neurological and mental health conditions are also among the leading contributors to disability-adjusted life years in the country.
1 In 7 Indians Affected By Mental Health Disorders; Govt To Launch NIMHANS-2 To Boost Care

Credit: Canva

One in seven Indians, or over 14 percent of the population, suffers from some form of mental health disorder. Amid an increasing treatment gap -- up to 90 percent -- seen in several states, especially in North India, the government today reiterated the plan of launching a second National Institute of Mental Health and Neurosciences (NIMHANS) in the northern states.

NIMHANS-2 was first announced by Finance Minister Nirmala Sitharaman during the Union Budget 2026-27, to deliver specialized care for mental health and neurological disorders in north India.

Health experts and policymakers, as part of the government-led Post-Budget Webinar series, highlighted the growing burden of mental and neurological disorders in India and also stressed the urgent need to strengthen institutional capacity to meet emerging healthcare demands.

"One in seven Indians is affected by mental health disorders, while several states continue to face a treatment gap ranging from 70 to 90 percent," the experts said.

Noting that Non-Communicable Diseases (NCDs) account for over 60 percent of deaths in the country, they added that "neurological and mental health conditions are among the leading contributors to disability-adjusted life years (DALYs)," among the citizens.

Need For Tertiary Neuro-psychiatric Care

To address these, the experts called for ramping up tertiary mental health institutions and expanding specialized services.

The session, moderated by Vijay Nehra, Joint Secretary, Ministry of Health and Family Welfare, highlighted that North India currently lacks adequate tertiary neuro-psychiatric care facilities. These include areas such as:

  • advanced neuroimaging,
  • neurocritical care,
  • specialized neurological services

Further, making a virtual address at the Post-Budget Webinar, Union Health Minister JP Nadda also highlighted the government’s focus on strengthening mental healthcare services in the country.

"NIMHANS-2 will be established in North India to expand advanced clinical care, training, and research," Nadda said.

"In addition, the Central Institute of Psychiatry, Ranchi, and the Lokopriya Gopinath Bordoloi Regional Institute of Mental Health, Tezpur, will be upgraded as regional apex institutions to strengthen mental healthcare services in the eastern and north-eastern regions," he added.

Meanwhile, the experts also stressed the need to improve services in underserved and geographically remote regions, including the northeastern states, through better infrastructure, capacity building, and targeted deployment of trained mental health professionals.

They also discussed strategies for expanding advanced neuro-psychiatric care and reinforcing India’s overall mental healthcare ecosystem. They proposed:

  • Adopting a hub-and-spoke model supported by digital health platforms

This would allow tertiary institutions and centers of excellence to provide technical guidance, specialist consultations, and clinical support to district hospitals and community-level health facilities.

"Such a model would strengthen referral pathways and ensure that specialized mental health services are accessible to people even in remote and rural areas," the experts said.

  • Integrating services under Tele-MANAS

Both existing and upcoming campuses of NIMHANS must be integrated , as this will enable a robust nationwide tele-mental health network that ensures

  • timely counselling,
  • psychological support,
  • specialist consultations

  • Digital follow-up systems

The experts called for the seamless integration of healthcare facilities, aligned with the vision of the Ayushman Bharat Digital Mission and the ABHA ID ecosystem. This, they said, will

  • enable continuity of care,
  • Improve monitoring of patients,
  • Lead to better clinical outcomes

  • A national Brain-Mind Cloud Network

The Network proposed under the National Health Mission would connect premier institutions such as All India Institute of Medical Sciences (AIIMS), state medical colleges, and primary healthcare centers through a digitally integrated platform.

It could also facilitate

  • unified mental health records,
  • AI-based screening tools,
  • data-driven clinical decision support systems,
  • tele-neuro-psychiatric hubs at regional centers.

End of Article